Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Nanotekniken kan revolutionera behandlingen av cancer - Ger nya möjligheter att målstyra läkemedel, men flera stora utmaningar återstår att tackla
KTH, School of Electrical Engineering (EES), Micro and Nanosystems.ORCID iD: 0000-0001-8248-6670
2017 (English)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 114Article in journal (Refereed) Published
Abstract [en]

Nanoparticles for cancer therapy Nanoparticles carry a big promise in oncology, for diagnosis/imaging, therapy, or both (theragnostics). As common in medical history, there is a huge gap between the exciting experimental possibilities and data and clinical studies making use of it. Of the cell-containing nanoparticles, only one formulation using gene-directed enzyme prodrug therapy (GDEPT) with CYP2B1 and ifosfamide was used in early clinical studies. Of the cell-free nanoparticles, some drug-releasing (doxorubicin) ones are in clinical use for trans-arterial chemo-embolization (TACE) in liver tumors and metastasis. Using liposomes, both paclitaxel and irinotecan have been used in pancreatic cancer as the model indication. Nanoparticle-albumin-bound paclitaxel (NAB-paclitaxel) has also been developed and is now registered as a drug for first-line therapy of pancreatic cancer, as is the liposomal irinotecan. The novel nanoparticle formulations carry a big promise for even better performance, both in diagnosis and therapy; however, few of these has entered the clinic as of today.

Place, publisher, year, edition, pages
2017. Vol. 114
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:kth:diva-218134PubMedID: 28675414Scopus ID: 2-s2.0-85033388628OAI: oai:DiVA.org:kth-218134DiVA, id: diva2:1160413
Note

QC 20171127

Available from: 2017-11-27 Created: 2017-11-27 Last updated: 2017-11-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

PubMedScopus

Authority records BETA

van der Wijngaart, Wouter

Search in DiVA

By author/editor
van der Wijngaart, Wouter
By organisation
Micro and Nanosystems
In the same journal
Läkartidningen
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 14 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf